Dr. Mangesh P. Kamath

Educational qualification

ECMO (European Certified in Medical Oncology) – 2017
European Society of Medical Oncology, Lugano, Switzerland
MRCP (Medical Oncology – SCE)- 2016
Royal College of Physicians, UK DM (Medical Oncology, Hemato-Oncology, BMT)-2016
Kidwai Memorial Institute of Oncology, Bangalore
DNB (Internal medicine) -2009 The Bangalore Hospital, Bangalore
MBBS-2004 Dr. B. R. Ambedkar Medical College, B’lore

Work experience:

• After completing my post-MBBS Internship, I worked as a Junior Resident in Mallige Medical Center.
• I then worked as a Junior Resident in CCU, Trinity Hospital and Heart Foundation.
• After achieving my post-graduation DNB degree in Internal Medicine, I worked as a Registrar in the ICU of Sagar Hospital, Jayanagar.
• I worked as a Registrar in the Department of Medicine in BGS Global Hospital. I worked as a Consultant Physician in Clumax Diagnostics, Apollo Clinics and South City
• Hospital; all centers located in South Bangalore.
• I worked as a Junior Consultant between August 2012 to July 2013 in the Department of Medical
  Oncology, Hemato-oncology and BMT Unit, HCG cancer hospitals, which is a 400 bedded Oncology Specialty hospital. During this period, I worked in both Solid Oncology and Hemato-Oncology departments. Our BMT team together conducted 23 Autologous Transplants and 11 Allogeneic Transplantations.
• I completed my DM Medical Oncology & Hemato-oncology training in the Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore which is a 500 bedded cancer institute and one of the premier regional cancer institutes in India. During my training, I performed 9 Autologous Bone Marrow Transplants for various indications in Hemato-oncology. I have cleared the MRCP Specialty Certification Exam. The certification was conferred by the Royal college of Physicians, UK.
• I have received my European certification in Medical Oncology (ECMO) from the prestigious European Society of Medical Oncology, Lugano, Switzerland. After my Sub-Specialty training, I worked as a Consultant in the Department of Medical oncology, Hemato-oncology and Bone Marrow Transplant Unit in HCG Hospital, Bangalore, from August 2016 to May 2017. During this period, I conducted 17 Allogeneic Transplants for AML, ALL, CML-BC and aplastic anemia and 27 Autologous Transplants for indications including Amyloidosis. I simultaneously treated and managed more than 100 patients presenting with Hematologic Malignancies, Aplastic Anemia, MDS and MPN.
• I was a Consultant Medical Oncologist in Mazumdar Shaw Cancer Center, a unit of Narayana Health City, Bangalore from May 2017 to August 2018. During my tenure there, I conducted more than 2000 chemotherapy sessions and was the principal investigator of three clinical trials. I was the Subject matter expert and Clinical Adoption specialist for IBM Watson for Oncology (WfO) from May 2018 to July 2019. During my time consulting for IBM, I played a role in the development of solutions for WfO to help enhance the artificial intelligence module as a ready reckoner for Oncologists to refer to, during their clinical practice. I had the privilege of interacting with oncologists practicing in different parts of the world. I gained tremendous perspective and experience about development of treatment protocols and strategies during my time spent with many Indian and International oncologists.
• I was the senior Consultant Medical Oncologist, Haemato-oncologist and BMT Physician, from August 2018 to November 2020, providing my services to BGS Global Gleneagles Hospitals, Bangalore as a part of a Comprehensive Oncology-Hematology Team which I co-founded. During my Tenure, I conducted 10 Bone marrow Transplantations and more than 2500 Chemotherapy sessions.
• I was the Medical Director and Senior Consultant Medical Oncologist for Oncology International Comprehensive Cancer Clinics, Bangalore from 1st April 2020 to 30th April 2021. I had a great experience not only in developing day care cancer center practice but also in developing protocols for faster treatment delivery with safety, and hospitality for cancer patients. Since this was the time of the initial days of the COVID pandemic, we administered more than 2000 chemotherapy sessions, safely and efficiently.
• I was a Senior Consultant Medical Oncologist, Hemato-Oncologist and BMT Physician at Fortis Hospitals, Bannerghatta Road, Nagarbhavi and Fortis La Femme from December 2020 to March 2023. I conducted 6 BMT’s (Autologous and Allogeneic) and more than 1000 Chemotherapy sessions for cancer patients during this period.
• I have been an associate consultant for Sankalp India Foundation since March 2021, whichenables and supports Bone marrow transplantations for children with Thalassemia, Aplastic Anemia, Sickle cell disease and many other transplant-curable pediatric diseases. Our transplant team has performed more than 100 bone marrow transplantations every month for children of families with poor financial resources.
• I was a senior consultant and Head of the Department of Medical Oncology, Hematology and BMT at the Bhagwan Mahaveer Jain hospitals, Bangalore from March 2021 to February 2023. I am currently the Additional Director in the Department of Oncology, Hematology and BMT at the Fortis Cancer Institute, Cunningham Road, Bangalore since February 2024. I also practice in my own multi-specialty cancer clinic named Healius Cancer & Hematology Clinic, Bangalore.
• I am an organizer, presenter and speaker during weekly multi-disciplinary meets and tumors board meets attended by Clinicians, Pathologists, Radiologists and Post-graduate students in the Hospital. I am an active speaker for periodically conducted medical oncology meets held in Bangalore. I am an active member of the Association of Medical Oncologists of India, a registered organization of Medical Oncologists in Karnataka.
• My core interests are in Cancer Research, Cancer prevention, Cancer genetics,  Immunotherapy, Targeted therapy, Geriatric Oncology and Stem cell transplantation and therapies.

Publications:
1) Efficacy study of metronomic chemotherapy in metastatic NSCLC. Abstract Number: e19092. Citation: J ClinOncol 31, 2013 (suppl; abstr e19092). Author(s): B. J. Srinivas, Nayak Radheshyam, C. Gunasagar, EriatGovind, Veldore H. Vidya, Rao M. Raghavendra, MangeshKamath, Roy Siddartha.
2) Metastatic Non-small lung cancer in South India: a regional demographic study; Accepted for publication in Indian Journal of Cancer. 2nd Author.
3) Pharmacoeconomic Advantage of Cisplatin and Etoposide chemoregimen for Metastatic Non Small Lung Cancer; An Indian Study. 1st Author. Accepted for publication in Lung India Journal.
4) Neuroendocrine neoplasms of the esophagus – emerging clinicopathological trends and outcomes of a rare entity. Annals of Oncology 12/2015; DOI:10.1093/annonc/mdv522.06. 1st Author.
5) Clinicopathological profile of Follicular Dendritic cell sarcoma of the head and neck. Published in Journal of Clinical and Diagnostic Research. 2016 Aug, Vol-10(8): XC08-XC11.
6) Clinicopathological profile of pure neuroendocrine neoplasms of the esophagus – A South Indian center experience. Accepted for publication in Journal of oncology.
7) Role of non- methotrexate based IAP chemotherapy regimen in osteosarcoma treatment. Under peer review.
8) Demographic profile of pediatric osteosarcoma in south India: a single institution experience. Ashok S Komaranchath, L. Appaji, K. C. Lakshmaiah , Mangesh Kamath , Rekha V Kumar. International Journal of Medical Research & Health Sciences. DOI: 10.5958/2319-5886.2015.00106.X.
9) An analysis of the demographic profile, clinical manifestations, investigations and outcome of paediatric myelodysplastic syndrome: A single centre, cross-sectional study. Lingegowda A, Kuntegowdenahalli L, Komaranchath A, Devi L, Kumari P, Kamath M. Int J Cancer Ther Oncol 2015; 3(3):337. DOI: 10.14319/ijcto.33.7.
10) A Case Report of a Metastatic Adenocarcinoma of Lung with Dual Positivity for EGFR Mutation and ALK Fusion. Published by Kamath M et al., J Nucl Med Radiat Ther 2015, 6:6.
11) Adenocarcinoma of the lung presenting as abdominal skip metastasis: a rare case report. Under peer review for publication in American journal of cancer case reports.
12) Acute Philadelphia chromosome positive bi-phenotypic leukemia presenting with bilateral orbital chloroma: a rare case report. Accepted for publication in American Journal of cancer case reports.
13) Role of Intraperitoneal Chemotherapy as the Third-Line Treatment of Epithelial Ovarian Cancer: A Case Report with Literature Review. Indian J Surg Oncol (September 2017)
8(3):433–435. https://doi.org/10.1007/s13193-017-0628-3.

Clinical Trials, Research and Studies:
1) Principal Investigator at A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two Sequence, Single Dose, Cross-Over Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 2 mg/mL of Cipla Limited, India, in comparison with Doxorubicin Hydrochloride Liposome Injection 2 mg/mL, of Sun Pharmaceutical Ind. Ltd, India, in the Patients of Ovarian Cancer under fasting
conditions.
2) Principal Investigator for A Multicenter, Double blind, Randomized, Parallel group study to assess the efficacy and safety of MYL-14020 compared with Avastin, in the first line treatment of patients with stage IV Non-squamous Non-small Lung Cancer.
3) Co-PI for A Phase III, Randomized, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SoC Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable, Non-small Cell Lung Cancer (NeoADAURA)
4) Co-PI for A Phase III, Double-blind, Placebo-controlled, Multi-centre International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-Small Cell Lung Cancer (AEGEAN).
5) Co-PI for A randomized, open label, multi-center, two-treatment, single-period, parallel group, single dose, Pharmacokinetic – Pharmaco-dynamic study of Test IP Leuprorelin acetate 11.25 mg of Sponsor with Reference IP Leuprorelin acetate 11.25 mg in male subjects with metastatic prostate cancer undergoing initial therapy under fasting condition.
6) Co-PI for A Phase III, Randomized, Multicenter, Double-blind, Placebo- controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2) study
7) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan vs. Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001) study
8) A Phase III, Randomized, Multi-center, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1) study

Academic Membership:
1) Member of Indian Society of Medical and Pediatric Oncology (ISMPO), India
2) Member of Association of Physicians of India (API), India
3) Member and Treasurer of Association of Medical Oncologists of India (AMOI) , India
4) Member of American Society of Clinical Oncology, USA
5) Member of European Society of Medical Oncology, Switzerland
6) Member of American Association of Cancer Research, USA
7) Member of European Association Cancer Research, Europe
8) Member of Royal College of Physicians, UK